Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-30T02:29:35.696Z Has data issue: false hasContentIssue false

Transcranial magnetic stimulation (TMS) in a child diagnosed with hypothalamic-pituitary tumour: a case report

Published online by Cambridge University Press:  19 July 2023

A. Moleon*
Affiliation:
1Hospital Universitario Virgen del Rocío 2Instituto Andaluz de Salud Cerebral, Sevilla
M. Martín-Bejarano
Affiliation:
2Instituto Andaluz de Salud Cerebral, Sevilla 3Hospital Universitario 12 de Octubre, Madrid 4Universidad de Cádiz, Cádiz
J. Narbona
Affiliation:
2Instituto Andaluz de Salud Cerebral, Sevilla
T. Rosa
Affiliation:
2Instituto Andaluz de Salud Cerebral, Sevilla
I. Pérez
Affiliation:
5Instituto Andaluz de Salud Cerebral, Huelva
M. García-Ferriol
Affiliation:
5Instituto Andaluz de Salud Cerebral, Huelva
R. Perea
Affiliation:
6Hospital Universitario Virgen Macarena, Sevilla
J. M. Oropesa
Affiliation:
7Hospital Juan Ramon Jimenez
T. Javier
Affiliation:
5Instituto Andaluz de Salud Cerebral, Huelva 8Universidad de Huelva, Huelva, Spain
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Central nervous system (CNS) tumours are the most common type of solid tumour in the paediatric population. Although advances in treatment have improved survival rates, there is a substantial body of literature documenting the potential long-term effects such as psychological, neurocognitive and health-related sequelae experienced by survivors of paediatric brain tumours. TMS is a non-invasive brain stimulation technique that uses electrical stimuli applied to the cranial surface to restore neuronal connections damaged because of CNS disruption (Burke et. al., 2019).

Objectives

To test the efficacy of TMS in a patient diagnosed with a CNS tumour who reported pain and suffered severe cognitive-behavioural alterations refractory to other pharmacological treatments.

Methods

Case Presentation. A 12-year-old boy diagnosed with a hypothalamic-pituitary tumour at the age of 9, having received surgical treatment, radiotherapy and chemotherapy. He suffered loss of vision, cognitive-behavioural and emotional sequelae, and pain, for which he received various pharmacological treatments without benefit. Treatment. The patient underwent a total of 25 sessions where each session took 20 minutes to complete for 3 sessions per week. TMS intervention consisted of 1200 inhibitory magnetic pulses with a frequency of 1hz on right DLPFC at an intensity of 110% of resting motor threshold. Stimulations were carried out using a Magventure MagPro X100 equipment with a double-cone coil. The clinical assessment included The Silhouettes Fatigue Scale (PHQ-9), Pain Catastrophizing Scale (PCS) and Numerical Rating Scale (NRS), verbal subtests of the Weschler Intelligence Scale for Children (WISC-V), Patient Health Questionnaire (PHQ-9) and the Sleep Disturbance Scale for Children, SDSC

Results

In the post-treatment clinical interview with the family, qualitative changes included a decrease in subjective complaints of pain and fatigue. The family reported that the child stopped sleeping tied up after the intervention and a significant change in slowness was observed, which was accompanied by a higher level of awareness and consequently a slight improvement at the behavioural level, which at the present time does allow for psychological intervention. The psychometric results were clinically improved for psychomotor activity, sleep, emotional alterations, and all cognitive domains.

Conclusions

25 sessions of TMS in the right DLPFC could show beneficial effects on pain, fatigue, cognition, health and sleep variables in patients with drug-resistant sequelae derived from CNS tumours. Longitudinal studies with larger sample sizes are needed to determine whether the effects observed after TMS intervention in paediatric patients with CNS diseases are significant.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.